EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CollPlant Biotechnologies EBITDA Margin % Related Terms
CollPlant Biotechnologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLGN vs CPMV, TCRT, DRMA: EBITDA Margin % Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies (CLGN) has a EBITDA Margin % of -3,979.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #821 out of 941 companies in the Biotechnology industry, placing it in the top 87.2%.
Is CollPlant Biotechnologies' EBITDA Margin % too high?
CollPlant Biotechnologies' current EBITDA Margin % is -3,979.45%. Based on the distribution chart, CollPlant Biotechnologies ranks #821 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' EBITDA Margin % compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #821 out of 941 companies for EBITDA Margin %. This places CollPlant Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current EBITDA Margin % is -3,979.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current EBITDA Margin % is -3,979.45%. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current EBITDA Margin % is -3,979.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
EBITDA Margin %: -3,979.45%
GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
